AGY — Allergy Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapFalling Star
- £125.58m
- £94.12m
- £84.33m
- 59
- 31
- 22
- 27
Annual income statement for Allergy Therapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
2017 June 30th | 2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | |||||
| Cost of Revenue | |||||
| Gross Profit | |||||
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | |||||
| Operating Profit | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | |||||
| Provision for Income Taxes | |||||
| Net Income After Taxes | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | |||||
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS |